Generated by AI
Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.
Website155 Bovet Road
San Mateo, CA, 94402
United States
The latest articles about SGMT.
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026Completed underwritten offering of Series A Common S
Summary of Nov 11's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about SGMT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.